I reported previously (3rd Sep) of Gilead’s $11.9 billion buyout of Kite – a biotech founded by Israel’s Professor Arie Belldegrun. Kite’s CAR-T technology cures non-Hodgkin lymphoma that kills 7,000 patients annually in the US alone. Prof Belldegrun gave his first interview since the deal.
http://www.globes.co.il/en/article-chemotherapy-will-become-just-a-bad-memory-1001206978